

Special Issue

Breast Cancer: From Pathophysiology to Therapeutic Strategies

Message from the Guest Editors

This Special Issue, “Breast Cancer: From Pathophysiology to Therapeutic Strategies”, will focus on the pathophysiology of breast cancer, new prognostic and/or predictive biomarkers of breast cancer, and novel therapeutic approaches for this disease.

Breast cancer is the most common cancer among women in the United States and around the world. The pathophysiology of breast cancer is complex, and numerous factors in a tumor and its microenvironment coordinately contribute to its progression and aggressiveness. Use of biomarkers has advanced breast cancer diagnosis and prognosis and prediction of therapeutic response. Identification of biomarkers has also advanced the development of targeted therapies for breast cancer. Novel therapeutic approaches and drug delivery systems have shown a promising beneficial effect in preclinical or clinical settings by affecting tumorigenesis, metastasis, and tumor–microenvironment interactions.

This Special Issue invites original articles and reviews on the topics of Pathophysiology, Biomarkers, New therapeutic approaches, Drug delivery systems and Immuno-oncology and the tumor microenvironment.

Guest Editors

Dr. Xuemei Xie

Dr. Toshiaki Iwase

Dr. Jangsoon Lee

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/157067

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).